
Sign up to save your podcasts
Or
What are informational meetings with the FDA, why should you schedule them, and how should they be conducted to make them valuable and worthwhile? It’s never too early to engage, interact, and collaborate with the FDA, or is it?
In this episode of the Global Medical Device Podcast Jon Speer and Etienne Nichols talk to Isabella Schmitt, Director of Regulatory Affairs at Proxima and Principal at M1 MedTech.
Isabella discusses the necessity of informational meetings and answers some commonly asked questions about them. Sometimes, it is too early to meet with the FDA if you don’t have the information needed to support questions.
Some of the highlights of this episode include:“With FDA, the relationship building from informational meetings is a huge component, and anything relational done with FDA is valuable and important.”
“It’s never too early for a pre-sub, but sometimes it is if you don’t actually have the information that you need to support the questions that you’re asking.”
“To find them valuable, you need to conduct them in a way that creates the value.”
“They like to attend informational meetings because we’re not really asking anything of them and they just get to be nerds again and geek out over the technology.”
“If you have a complex product, I would plan to do an informational meeting before pre-subs, just to talk about the product and get FDA to understand it foundationally.”
Links:FDA - Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
Isabella Schmitt
Isabella Schmitt on LinkedIn
Proxima CRO
M1 MedTech
Inventing Tomorrow Podcast
True Quality 2022
Greenlight Guru YouTube Channel
MedTech True Quality Stories Podcast
Greenlight Guru
4.8
9191 ratings
What are informational meetings with the FDA, why should you schedule them, and how should they be conducted to make them valuable and worthwhile? It’s never too early to engage, interact, and collaborate with the FDA, or is it?
In this episode of the Global Medical Device Podcast Jon Speer and Etienne Nichols talk to Isabella Schmitt, Director of Regulatory Affairs at Proxima and Principal at M1 MedTech.
Isabella discusses the necessity of informational meetings and answers some commonly asked questions about them. Sometimes, it is too early to meet with the FDA if you don’t have the information needed to support questions.
Some of the highlights of this episode include:“With FDA, the relationship building from informational meetings is a huge component, and anything relational done with FDA is valuable and important.”
“It’s never too early for a pre-sub, but sometimes it is if you don’t actually have the information that you need to support the questions that you’re asking.”
“To find them valuable, you need to conduct them in a way that creates the value.”
“They like to attend informational meetings because we’re not really asking anything of them and they just get to be nerds again and geek out over the technology.”
“If you have a complex product, I would plan to do an informational meeting before pre-subs, just to talk about the product and get FDA to understand it foundationally.”
Links:FDA - Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
Isabella Schmitt
Isabella Schmitt on LinkedIn
Proxima CRO
M1 MedTech
Inventing Tomorrow Podcast
True Quality 2022
Greenlight Guru YouTube Channel
MedTech True Quality Stories Podcast
Greenlight Guru
177 Listeners
7,827 Listeners
30,891 Listeners
32,108 Listeners
66 Listeners
43,250 Listeners
1,041 Listeners
111,470 Listeners
56,179 Listeners
20 Listeners
5 Listeners
8,677 Listeners
34 Listeners
2,110 Listeners
3 Listeners